Quite interestingly, depletion of ATXN2 expression by antisense oligonucleotides (ASOs) has shown massive benefit as a therapeutic intervention for ALS in mice and SCA2 patients [55,56]. The gene discussed is ATXN2; the disease is amyotrophic lateral sclerosis.